Testing plixorafenib, alone or with retifanlimab, for BRAF-changed glioma
Original title: A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a very early test in people, so it is far from routine care.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests two drugs in people whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary has a BRAF: A gene in a pathway that tells cells to divide. Some tumors carry a change in it. There are drugs made to target that change, so your team may test for it. See the glossary gene change.
Who this trial is for. This trial is for people with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary that has a BRAF: A gene in a pathway that tells cells to divide. Some tumors carry a change in it. There are drugs made to target that change, so your team may test for it. See the glossary gene change, and that kept growing after earlier treatment. It tests the drug plixorafenib by itself or together with another drug, retifanlimab.
Where it stands. This trial has not reported results. The team is checking bits of tumor DNA in the blood and in the fluid around the brain and spine. They look at it before treatment starts and again over time. They want to see if those tests can pick up changes during treatment. The answer is not in yet.
What this means, and what it doesn't
What it could mean: If you have a glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary with a BRAF: A gene in a pathway that tells cells to divide. Some tumors carry a change in it. There are drugs made to target that change, so your team may test for it. See the glossary change that came back after other treatment, this is one study to know about. You could ask your care team if it fits your situation. They can help you weigh it against your other options.
What it doesn't mean: This does not mean the drugs work. A trial is a test, not a proven treatment. Joining a study is not a promise that you will be helped. It is not a cure, and it is not care your own doctor can give you today.
Source: ClinicalTrials.gov, September 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.